Characteristicsa | Valid cases | Intensity of therapy | ||
---|---|---|---|---|
One agent | Two agents | Three or more agents | ||
Primary prevention of CVD | ||||
Proportions of patients on glucose lowering therapy achieving and not achieving treatment target (%, 95 % CI) | ||||
HbA1c ≤ 7.5% | 595 | 63.9 (59.9-67.6) | 34.6 (30.9-38.5) | 1.5 (0.8-2.9) |
HbA1c > 7.5% | 304 | 43.4 (38.0-49.9) | 51.0 (45.4-56.6) | 5.6 (3.5-8.8) |
P < 0.001b | ||||
Proportions of patients on anti-hypertensive therapy achieving and not achieving treatment target (%, 95% CI) | ||||
SBP ≤ 140 mmHg | 414 | 43.7 (39.0-48.5) | 29.0 (24.8-33.5) | 27.3 (23.2-31.8) |
SBP > 140 mmHg | 258 | 35.3 (29.7-41.3) | 28.3 (23.1-34.1) | 36.4 (30.7-42.3) |
P=0.028b | ||||
DBP ≤ 85 mmHg | 499 | 41.1 (36.9-45.5) | 28.7 (24.9-32.8) | 30.3 (26.4-34.4) |
DBP > 85 mmHg | 172 | 39.0 (32.0-46.4) | 28.5 (22.2-35.7) | 32.6 (26.0-39.9) |
P=0.834b | ||||
Secondary prevention of CVD | ||||
Proportions of patients on glucose lowering therapy achieving and not achieving treatment target (%, 95% CI) | ||||
HbA1c ≤ 7.5% | 183 | 58.5 (51.2-65.4) | 37.7 (31.4-44.9) | 3.8 (1.7-7.8) |
HbA1c > 7.5% | 97 | 48.5 (38.8-58.3) | 47.4 (37.8-57.3) | 4.1 (1.3-10.5) |
P=0.269b | ||||
Proportions of patients on anti-hypertensive therapy achieving and not achieving treatment target (%, 95% CI) | ||||
SBP ≤ 140 mmHg | 205 | 31.7 (25.7-38.4) | 30.2 (24.4-36.9) | 38.0 (31.7-44.9) |
SBP > 140 mmHg | 114 | 21.1 (14.5-29.5) | 34.2 (26.1-43.3) | 44.7 (35.9-53.9) |
P=0.125b | ||||
DBP ≤ 85 mmHg | 268 | 28.4 (23.3-34.0) | 31.7 (26.4-37.5) | 39.9 (34.2-45.9) |
DBP > 85 mmHg | 51 | 25.5 (15.4-39.0) | 31.4 (20.3-45.1) | 43.1 (30.5-56.7) |
P=0.888b |